BREAST

 

 

40601 (CALGB) - RANDOMIZED PHASE III TRIAL OF PACLITAXEL COMBINED WITH TRASTUZUMAB, LAPATINIB, OR BOTH AS NEOADJUVANT TREATMENT OF HER2 POSITIVE PRIMARY BREAST CANCER 

 

40101 (CALGB) - CYCLOPHOSPHAMIDE AND DOXORUBICIN (CA) (4 vs. 6 CYCLES) VERSUS PACLITAXEL (4 vs. 6 CYCLES) AS ADJUVANT THERAPY FOR WOMEN WITH NODE-NEGATIVE BREAST CANCER: A 2X2 FACTORIAL PHASE III RANDOMIZED STUDY

 

3144A2-3004-WW (PHARMA) - PHASE III, RANOMIZED DOUBLE BLIND STUDY OF NERATINIB VERSUS PLACEBO IN WORMEN WITH EARLY STAGE erbB-2 OVEREXPRESSED/AMPLIFIED BREAST CANCER AFTER ADJUVANT TREATMENT WITH TRASTUZUMAB

 

ECOG PACCT-1 (CALGB) – PROGRAM FOR THE ASSESSMENT OF CLINICAL CANCER TESTS (PACCT-1): TRIAL ASSIGNING INDIVIDUALIZED OPTIONS FOR TREATMENT: THE TAILORX TRIAL

 

E5103 (CALGB) - A DOUBLE-BLIND PHASE III TRAIL OF DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL WITH BEVACIZUMAB OR PLACEBO IN PATIENTS WITH LYMPH NODE POSITIVE AND HIGH RISK LYMPH NODE NEGATIVE BREAST CANCER

 

N063D (CALGB) - A RANDOMIZED, MULTI-CENTRE, OPEN-LABEL, PHASE III STUDY OF ADJUVANT LAPATINIB, TRASTUZUMAB, THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2/ErbB2 POSITIVE PRIMARY BREAST CANCER (NEO-ADJUVANT or ADJUVANT STUDY)

 

CRAD001W2301- Phase III Randomized, Doubl-Blind, Placebo-controlled study of Everolimus plus Trastuzamab and Vinorelbine in the Treatment of Women with Her2 Postive locally advanced or Metastatic Breast Cancer previously treated with Taxanes and Resistant to Trastuzumab

 

08047 (VEEDA) - A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EVEROLIMUS IN COMBINATION WITH EXEMESTANE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO ARE REFRACTORY TO LETROZOLE OR ANASTROZOLE

 

08002 (VEEDA) - A PHASE II, SINGLE-ARM, MULTI-CENTER STUDY EVALUATING THE COMBINATION OF VINORELBINE AND LAPATINIB IN WOMEN WITH ErbB2 OVEREXPERSSING METASTATIC BREAST CANCER

 

40502 (CALGB) - A RANDOMIZED PHASE III TRIAL OF WEEKLY PACLITAXEL COMPARED TO WEEKLY NANOPARTICLE ALBUMIN BOUND NAB-PACLITAXEL OR IXABEPILONE COMBINED WITH BEVACIZUMAB AS FIRST-LINE THERAPY FOR LOCALLY RECURRENT OR METASTATIC BREAST CANCER

 

40603 (CALGB) - RANDOMIZED PHASE II 2 X 2 FACTORIAL TRIAL OF THE ADDITION OF CARBOPLATIN +/- BEVACIZUMAB TO NEOADJUVANT WEEKLY PACLITAXEL FOLLOWED BY DOSE-DENSE AC IN HORMONE RECEPTOR-POOR/HER2 NEGATIVE RESECTABLE BREAST CANCER

 

TUMOR REGISTRY STUDY 01-075 (DATA ONLY) - A PILOT PHASE OBSERVATIONAL REGISTRY STUDY TO EVALUATE THE BASELINE MEASUREMENTS AND PATTERNS OF ADJUVANT AND NEOADJUVANT TREATMENT IN PATIENTS FOR WHOM AN ONCOTYPE DX BREAST CANCER RECURRENCE SCORE IS OBTAINED

 

COLON/RECTAL

 

80405 (CALGB) - A PHASE III TRIAL OF IRINOTECAN / 5FU/ LEUCOVORIN OR OXALIPLATIN / 5FU/ LEUCOVORIN WITH BEVACIZUMAB, OR CETUXIMAB (C225), OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (STUDY ON HOLD)

 

E5202 (CALGB) - A RANDOMIZED PHASE III STUDY COMPARING 5-FU, LEUCOVORIN AND OXALIPLATIN VERSUS 5-FU, LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB IN PATIENTS WITH STAGE II COLON CANCER AT HIGH RISK FOR RECURRENCE TO DETERMINE PROSPECTIVELY THE PROGNOSTIC VALUE OF MOLECULAR MARKERS

 

 ITP

 

20080009 (PHARMA) - A PROSPECTIVE, PHASE IV, OPEN-LABEL, MULTI-CENTER STUDY EVALUATING CHANGES IN BONE MARROW MORHOLOGY IN ADULT SUBJECTS RECEIVING ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA ASSOCIATED WITH IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA PURPURA (ITP)

 

HEAD & NECK

 

 E1305 (CALGB) - A PHASE III RANDOMIZED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER

 

LEUKEMIA

 

10603 (CALGB) - A PHASE III RANDOMIZED, DOUBLE BLIND STUDY OF INDUCTION (DAUNORUBICIN/CYTARABINE) AND CONSOLIDATION (HIGH-DOSE CYTARBINE) CHEMOTHERAPY + MIDOSTAURIN (PKC412) (IND#101261) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS < 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA

 

LUNG

E1505 (CALGB) - A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR PATIENTS WITH COMPLETELY RESECTED STAGE I B (> 4 CM) - IIIA NON-SMALL CELL LUNG CANCER (NSCLC)

 

08036 (VEEDA) - RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF PEMETREXED PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED AND BEVACIZUMAB VERSUS PACLITAXEL PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB OR IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER

 

30607 (CALGB) - RANDOMIZED, PHASE III, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF SUNITINIB AS MANTENANCE THERAPY IN NON-PROGRESSING PATIENTS FOLLOWING AN INITIAL FOUR CYCLES OF PLATINUM-BASED COMINATION CHEMO IN ADVANCED, STAGE IIIB-IV NON-SMALL CELL LUNG CANCER

 

08030 (VEEDA) - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DARBEPOETIN ALFA ADMINISTERED AT 500MG ONCE-EVERY-3-WEEKS IN ANEMIC SUBJECTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER RECEIVING MULTI-CYCLE CHEMOTHERAPY

 

 MELANOMA

09030 (VEEDA) - PHASE III, TWO-ARM, RANDOMIZED, OPEN-LABEL INVESTIGATION OF TASISULAM VS PACLITAXEL ADMINISTERED AFTER 1 PRIOR SYSTEMIC TREATMENT REGIMEN CONTAINING EITHER DACARBAZINE OR TEMOZOLAMIDE FOR METASTATIC MELANOMA

 

E1697 (CALGB) - PHASE III RANDOMIZED STUDY OF FOUR WEEKS HIGH DOSE IFN-a2b IN STAGE T2b No, T3a-bNo, T4a-b No, AND T1-4, N1a, 2a (MICROSCOPIC) MELANOMA

 

PANCREATIC

 

CA046 (PHARMA) - A RANOMIZED PHASE III STUDY OF WEEKLY ABI-007 PLUS GEMCITABINE VS GEMCITABINE ALONE IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS

 

 

RENAL

 

E2805 (CALGB) - A RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL OF ADJUVANT SUNITINIB VERSUS SORAFENIB VERSUS PLACEBO IN PATIENTS WITH RESECTED RENAL CELL CARCINOMA

 

3066K1-404-WW - (PHARMA) - (OPEN ONLY TO LAKE HEFNER AND MERCY SITES) A RANDOMIZED TRIAL OF TEMSIROLIMUS VERSUS SORAFENIB AS SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAVE FAILED FIRST-LINE SUNITINIB THERAPY